Health Condition 1: A499- Bacterial infection, unspecified Health Condition 2: B374- Candidiasis of other urogenital sites Health Condition 3: B373- Candidiasis of vulva and vagina Health Condition 4: N898- Other specified noninflammatory disorders of vagina Health Condition 5: N390- Urinary tract infection, site notspecified
Conditions
Interventions
Intervention1: Developed diagnostic device: The developed diagnostic device will be validated with vaginal swab and urine samples from Patients with the vaginal and/or urinary tract infection and heal
Sponsors
Reckitt Benckiser (India) Pvt. Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: Control group: Inclusion criteria: Any Healthy individuals/Patients without Vaginal and Urinary tract infection visiting the OBG department, Age group 20-50. Patient group: Inclusion criteria: Patients with vaginal infection and/or urinary tract infection, Age group 20-50.
Exclusion criteria
Exclusion criteria: Control group: Exclusion criteria: Pregnant women, Vulnerable group, Patients who recently consumed antibiotics and antifungals, Patients having viral infections, symptoms of jaundice, hepatitis, HIV, Leptospira, Chyluria etc. Patient group: Exclusion criteria: Pregnant women, Vulnerable group, Patients who recently consumed antibiotics and antifungals, Patients having viral infections, symptoms of jaundice, hepatitis, HIV, Leptospira, Chyluria etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The developed diagnostic platform will be tested for diagnostic accuracy in terms of sensitivity, specificity and other parameters using the clinical vaginal swab and urine samples, and compared with the Gold standard method i.e. microbial culture.Timepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Naresh Kumar Mani
Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal
Outcome results
None listed